Evidence for a Proinflammatory and Proteolytic Environment in Plaques from Endarterectomy Segments of Human Carotid Arteries

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 24, Issue 1, 2004, Pages 129-135

  Formato, Marilena ^b   Farina, Miriam ^a   Spirito, Rita ^c   Maggioni, Marco ^c   Guarino, Anna ^c   Cherchi, Gian Mario ^b   Biglioli, Paolo ^c   Edelstein, Celina ^a   Scanu, Angelo M ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF SASSARI   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

Apolipoproteins; Interleukins; Metalloproteinases; Proteoglycans; Stable and unstable carotid plaques

Indexed keywords

APOLIPOPROTEIN A; APOLIPOPROTEIN B; BIGLYCAN; DECORIN; GELATINASE A; GELATINASE B; GUANIDINE; INTERLEUKIN 18; INTERLEUKIN 6; INTERLEUKIN 8; SODIUM CHLORIDE; VERSICAN;

AGED; ARTICLE; ATHEROMA; ATHEROSCLEROTIC PLAQUE; CAROTID ENDARTERECTOMY; CONCENTRATION RESPONSE; CORRELATION ANALYSIS; FEMALE; FRAGMENTATION REACTION; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN DEGRADATION; ULTRACENTRIFUGATION; WESTERN BLOTTING;

AGED; APOLIPOPROTEINS; BIOLOGICAL MARKERS; CAROTID STENOSIS; ENDARTERECTOMY, CAROTID; EXTRACELLULAR MATRIX PROTEINS; FEMALE; GUANIDINE; HUMANS; INTERLEUKINS; MALE; MATRIX METALLOPROTEINASES; MIDDLE AGED; PEPTIDE FRAGMENTS; PROTEINS; PROTEOGLYCANS; VASCULITIS;

EID: 0346492595     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.0000104013.71118.53     Document Type: Article

References (33)

1. Libby P. Inflammation in atherosclerosis. Nature. 2002;420:868-874.
2. Fortunato JE, Bassiouny HS, Song RH, Kocharian H, Glagov S, Edelstein C, Scanu AM. Apolipoprotein(a) fragments in relation to human carotid plaque instability. J Vasc Surg. 2000;32:555-563.
3. Hoff HF, O'Neil J, Smejkal GB, Yashiro A. Immuno-chemically detectable lipid-free apo(a) in plasma and in human atherosclerotic lesions. Chem Phys Lipids. 1994;67-68:271-280.
4. Steinberg D, Lewis A. Conner Memorial Lecture: oxidative modifications of LDL and atherogenesis. Circulation. 1997;95:1062-1071.
5. Wight TN. The vascular extracellular matrix. In: Fuster V, Ross R, Topol E, eds. Atherosclerosis and Coronary Artery Disease. Philadelphia: Lippincott-Raven; 1996:421-440.
6. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the distribution of low density lipoprotein cholesterol in plasma without the use of the preparative centrifuge. Clin Chem. 1972;18:499-502.
7. Fless GM, Snyder ML, Scanu AM. Enzyme-linked immunoassay Lp(a). J Lipid Res. 1989;30:651-662.
8. Scanu AM, Hinman J. Issues concerning the monitoring of statin therapy in hypercholesterolemic subjects with high plasma lipoprotein(a) levels. Lipids. 2002;37:439-444.
9. Lowry OH, Rosebrough NJ, Farr A, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951;193:265-275.
10. Glantz SA. Primer of Biostatistics, 4th ed. New York: McGraw-Hill; 1997.
11. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2497.
12. Galis ZS, Sukhova GK, Lark MW, Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest. 1994;94:2493-2503.
13. Loftus IM, Naylor AR, Goodall S, Crowther M, Jones L, Bell PR, Thompson MM. Increase matrix metalloproteinase 9 activity in unstable plaques: a potential role in acute plaque disruption. Stroke. 2000;31:40-47.
14. Ridker PM, Rifai N, Stampfer MJ, Hennekens CH. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation. 2000;101:1767-1772.
15. Pantsulaia I, Trofimov S, Kobyliansky E, Livshits G. Genetic level and environmentaI influences on IL-6 and TNF-α plasma levels in apparently healthy population. Cytokine. 2002;19:138-146.
16. Zhou RH, Shi Q, Gao HQ, Shen BJ. Changes in serum interleukin-8 and interleukin-12 levels in patients with ischemic heart disease in a Chinese population. J Atheroscler Thromb. 2001;8:30-32.
17. Lee SH, Jeong MH, Bae HR, Jeong SJ, Jang JY, Kim SH, Kim JW, Cha JK. Circulating levels of interleukin-8 and vascular endothelial growth factor in patients with carotid stenosis. J Korean Med Sci. 2001;16:198-203.
18. Lankenberg S, Tiret L, Bickel C, Peetz D, Cambien F, Meyer J, Rupprecht HJ, and AtheroGene Investigators. Interleukin-18 is a strong predictor of cardiovascular death in stable and unstable angina. Circulation. 2002;106:24-30.
19. Yamashita H, Shimada K, Seki E, Mokuno H, Daida H. Concentrations of interleukins, interferon, and C-reactive protein in stable and unstable angina pectoris. Am J Cardiol. 2003;91:133-136.
20. Jones SA, Rose-John S. The role of soluble receptors in cytokine biology: the agonistic properties of the sIL-6R/IL-6 complex. Biochim Biophys Acta. 2002;1592:251-63.
21. Zhang W, Chen H. The study on the interleukin-8 (IL-8). Sheng Wu Yi Xue Gong Cheng Xue Za Zhi. 2002;19:697-702.
22. Nakanishi K, Yoshimoto T, Tsutsui H, Okamura H. Interleukin-18 is a unique cytokine that stimulates both Th1 and Th2 responses depending on its cytokine milieu. Cytokine Growth Factor Rev. 2001;12:53-72.
23. Williams KJ, Tabas I. The response-to-retention hypothesis of early atherogenesis. Arterioscler Thromb Vasc Biol. 1995;15:551-561.
24. Scanu AM. Lipoprotein(a) and the atherothrombotic process: mechanistic insights and clinical implications. Curr Atheroscl Rep. 2003;5:106-113.
25. Edelstein C, Nakajima K, Pfaffinger D, Scanu AM. Oxidative events cause degradation of apoB-100 but not of apo(a) and facilitate enzymatic cleavage of both proteins. J Lipid Res. 2001;42:1664-1670.
26. Klezovitch O, Formato M, Cherchi GM, Weisgraber KM, Scanu AM. Structural determinants in the C-terminal domain of apolipoprotein E mediating binding to the protein core of human aortic biglycan. J Biol Chem. 2000;275:18913-18918.
27. Klezovitch O, Scanu AM. Domains of apolipoprotein E involved in the binding to the protein core of biglycan of the vascular extracellular matrix. Trends Cardiovasc Med. 2001;11:263-268.
28. Kazushi I, Hiramatsu A, Fukushima D, Pierschbacher MD, Okada Y. Degradation of decorin by matrix metalloproteinases: Identification of the cleavage sites, kinetic analyses and transforming growth factor-β1 release. Biochem J. 1997;322:809-814.
29. Hobbs HH, White AL. Lipoprotein(a): intrigues and insights. Curr Opin Lipidol. 1999;10:225-236.
30. Assmann G, Nofer J-R. Atheroprotective effects of high-density lipoproteins. Annu Rev Med. 2003;54:321-341.
31. Smith EB Thompson WD, Crosbie L, Stirk CM. Fibrinogen/fibrin in atherogenesis. Eur J Epidemiol. 1992;8:83-87.
32. Bini A, Fenoglio JJ, Mesa-Tejada R, Kudryck, B Kaplan KL. Identification and distribution of fibrinogen, fibrin and fibrin(ogen) degradation products in atherosclerosis: use of monoclonal antibodies. Arter Thromb Vasc Biol. 1989;9:109-121.
33. Naito M, Stirk CM, Smith EB, Thompson DW. Smooth muscle cell outgrowth stimulated by fibrin degradation products: the potential role of fibrin fragment E in restenosis and atherogenesis. Thrombosis Res. 2000;98:165-174.